Phase I-II study of Dasatinib and Erlotinib in Non-Small Cell Lung Cancer

Trial Profile

Phase I-II study of Dasatinib and Erlotinib in Non-Small Cell Lung Cancer

Completed
Phase of Trial: Phase I/II

Latest Information Update: 29 Jun 2016

At a glance

  • Drugs Dasatinib (Primary) ; Erlotinib (Primary)
  • Indications Non-small cell lung cancer; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 26 May 2016 Status changed from discontinued to completed.
    • 11 Jun 2014 Trial status changed from active, no longer recruiting to discontinued as reported by M.D. Anderson Cancer Center.
    • 20 Jul 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top